Jump to content

Masitinib

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Masitinib
Clinical data
Trade namesMasivet, Kinavet
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H30N6OS
Molar mass498.65 g·mol−1
3D model (JSmol)
  • O=C(c1ccc(cc1)CN2CCN(C)CC2)Nc3cc(c(cc3)C)Nc4nc(cs4)c5cccnc5
  • InChI=InChI=1S/C28H30N6OSc1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
  • Key:WJEOLQLKVOPQFV-UHFFFAOYSA-N

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumours in animals, specifically dogs.[1][2] Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. Masitinib has been studied for several human conditions including melanoma, multiple myeloma, gastrointestinal cancer, pancreatic cancer, Alzheimer disease, multiple sclerosis, rheumatoid arthritis, mastocytosis, amyotrophic lateral sclerosis and COVID-19.[3][4][5]

Mechanism of action

Masitinib is a tyrosine kinase inhibitor which inhibits tyrosine kinases, enzymes responsible for the activation of many proteins by signal transduction cascades. Specifically, masitinib targets the receptor tyrosine kinase c-Kit which is found to be overexpressed or mutated in several types of cancer.[2][6] In addition to cKit, Masitinib also has additional targets, and it inhibits platelet derived growth factor receptor (PDGFR), lymphocyte-specific protein tyrosine kinase (Lck), focal adhesion kinase (FAK) and fibroblast growth factor receptor 3 (FGFR3) as well as CSF1R.[7][8]

Masitinib has been shown to block the replication of SARS-CoV-2 by inhibiting its main protease, 3CLpro. Masitinib showed >200-fold reduction in viral titers in the lungs and nose of mice infected with SARS-CoV-2.[3]

Society and culture

Masitinib was under investigation for the treatment of systemic mastocytosis (Masipro) but approval was denied in the EU in 2017 due to concerns "about the reliability of the study results" and major changes to the study design.[9][10][11] European approval of masitinib for treatment of amyotrophic lateral sclerosis (Alsitek) was also refused in 2018.[12][13]

In June 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended the refusal of a marketing authorization for Masitinib AB Science, a medicine intended for the treatment of amyotrophic lateral sclerosis, a rare disease of the nervous system leading to loss of muscle function and paralysis.[14][15] In October 2024, following a re-examination, the CHMP confirmed its recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science.[16]

References

  1. ^ Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. (2008). "Masitinib is safe and effective for the treatment of canine mast cell tumors". Journal of Veterinary Internal Medicine. 22 (6): 1301–1309. doi:10.1111/j.1939-1676.2008.0190.x. PMID 18823406.{{cite journal}}: CS1 maint: overridden setting (link)
  2. ^ a b Information about Masivet Archived 15 November 2017 at the Wayback Machine at the European pharmacy agency website
  3. ^ a b Drayman N, DeMarco JK, Jones KA, Azizi SA, Froggatt HM, Tan K, et al. (August 2021). "Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2". Science. 373 (6557): 931–936. Bibcode:2021Sci...373..931D. doi:10.1126/science.abg5827. PMC 8809056. PMID 34285133.{{cite journal}}: CS1 maint: overridden setting (link)
  4. ^ "Orphan designation EU/3/16/1722 for masitinib mesilate for the treatment of amyotrophic lateral sclerosis". European Medicines Agency. 17 September 2018. Archived from the original on 17 October 2017. Retrieved 29 November 2016.
  5. ^ Folch J, Petrov D, Ettcheto M, Pedrós I, Abad S, Beas-Zarate C, et al. (June 2015). "Masitinib for the treatment of mild to moderate Alzheimer's disease". Expert Review of Neurotherapeutics. 15 (6): 587–596. doi:10.1586/14737175.2015.1045419. PMID 25961655. S2CID 39839943.{{cite journal}}: CS1 maint: overridden setting (link)
  6. ^ Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, et al. (September 2009). "Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT". PLOS ONE. 4 (9): e7258. Bibcode:2009PLoSO...4.7258D. doi:10.1371/journal.pone.0007258. PMC 2746281. PMID 19789626.{{cite journal}}: CS1 maint: overridden setting (link)
  7. ^ Gil da Costa RM (July 2015). "C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic". Veterinary Journal. 205 (1): 5–10. doi:10.1016/j.tvjl.2015.05.002. hdl:10216/103345. PMID 26021891.
  8. ^ Trias E, Ibarburu S, Barreto-Núñez R, Babdor J, Maciel TT, Guillo M, et al. (July 2016). "Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis". Journal of Neuroinflammation. 13 (1): 177. doi:10.1186/s12974-016-0620-9. PMC 4940876. PMID 27400786.{{cite journal}}: CS1 maint: overridden setting (link)
  9. ^ "Masipro EPAR". European Medicines Agency. 18 May 2017. Archived from the original on 30 May 2023. Retrieved 12 July 2024.
  10. ^ Refusal of the marketing authorisation for Masipro (masitinib). Archived 15 March 2018 at the Wayback Machine (PDF) EMA, 15 September 2017; retrieved 21 September 2017.
  11. ^ "Masipro (masitinib)". Union Register of refused medicinal products for human use. Public Health - European Commission. Archived from the original on 11 June 2018. Retrieved 12 July 2024.
  12. ^ "Alsitek EPAR". European Medicines Agency. 18 April 2018. Archived from the original on 10 August 2023. Retrieved 12 July 2024.
  13. ^ "Alsitek (masitinib)". Union Register of refused medicinal products for human use. Public Health - European Commission.
  14. ^ "Masitinib AB Science EPAR". European Medicines Agency (EMA). 27 June 2024. Retrieved 12 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  15. ^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024". European Medicines Agency. 28 June 2024. Archived from the original on 12 July 2024. Retrieved 12 July 2024.
  16. ^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024". European Medicines Agency (EMA). 18 October 2024. Retrieved 21 October 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Masitinib&oldid=1263096117"